.Attribute Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a median follow-up of 11 months, patients with metastatic stomach growths that received biomarker-matched treatments based upon spreading growth DNA profiling presented a higher professional benefit than those getting unparalleled treatment.